Barclays PLC Boosts Stock Position in Sera Prognostics, Inc. (NASDAQ:SERA)

Barclays PLC increased its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 321.6% during the third quarter, HoldingsChannel reports. The institutional investor owned 39,450 shares of the company’s stock after acquiring an additional 30,093 shares during the period. Barclays PLC’s holdings in Sera Prognostics were worth $308,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after purchasing an additional 2,826 shares in the last quarter. American Century Companies Inc. lifted its stake in Sera Prognostics by 12.7% in the 2nd quarter. American Century Companies Inc. now owns 25,682 shares of the company’s stock valued at $152,000 after buying an additional 2,891 shares in the last quarter. Quest Partners LLC boosted its holdings in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares during the last quarter. MetLife Investment Management LLC increased its stake in Sera Prognostics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock worth $135,000 after buying an additional 9,722 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Sera Prognostics during the third quarter valued at approximately $78,000. Institutional investors and hedge funds own 54.64% of the company’s stock.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA opened at $6.42 on Monday. The business’s 50 day moving average price is $7.37 and its 200-day moving average price is $7.33. Sera Prognostics, Inc. has a 1 year low of $4.98 and a 1 year high of $12.35. The firm has a market capitalization of $216.80 million, a PE ratio of -6.48 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the firm earned ($0.23) earnings per share. As a group, analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Insiders Place Their Bets

In other Sera Prognostics news, General Counsel Benjamin Jackson sold 13,272 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.42, for a total value of $98,478.24. Following the completion of the sale, the general counsel now directly owns 128,473 shares of the company’s stock, valued at $953,269.66. This trade represents a 9.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul Kearney sold 4,078 shares of Sera Prognostics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $7.32, for a total value of $29,850.96. Following the transaction, the insider now owns 176,889 shares in the company, valued at approximately $1,294,827.48. This represents a 2.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,215 shares of company stock valued at $666,835 in the last ninety days. 15.80% of the stock is currently owned by corporate insiders.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.